Ludhiana: The activists of Kale Pani Da Morcha have criticised the authorities for failing to fulfill their promise to close down the common effluent treatment plant (CETP) at Bahadur K Road, even after two days have passed. They said that instead of taking action, the authorities have deployed police to guard the outlet. The activists have threatened to stage another protest to address the pollution in the drain. On Dec 3, activists staged a protest on Ferozepur Road, demanding the closure of CETP outlets at Tajpur Road. In response, administration officials assured the activists that they would close one outlet at Bahadur K Road within two days and review the legal opinion before addressing the remaining two outlets. Activist Jaskirat Singh said: “On Dec 4, we submitted a memorandum to additional deputy commissioner Amarjit Bains to remind him of the promise.” He added that authorities have even deployed police at one side of the outlet to apprehend anyone who tries to intervene. Another activist, Kuldeep Khaira, said: “We will not let this issue die down here. If people can gather once for this cause, they can come again.” “The affected people participated in the protest to stand against the polluters and shared the issues they face due to water pollution,” he said. Chief engineer of PPCB, RK Ratra, could not be reached for comments. However, sources said PPCB officials claimed they were not consulted when the promises were made, and therefore, they cannot take any action. We also published the following articles recently Police meet dyeing unit owners as activists prep to close CETPs Tensions are brewing in Ludhiana as Kala Pani Da Morcha activists plan to shut down dyeing unit CETPs on December 3rd, citing pollution of the Buddha Dariya. Police have assured protection to the CETPs after the Punjab Dyers Association raised concerns. Greenpeace activists board tanker in plastic protest Greenpeace activists boarded a tanker near South Korea, protesting plastic production and urging a robust global treaty to curb pollution. The activists painted "PLASTIC KILLS" on the vessel and established a temporary camp, disrupting cargo loading. Negotiations in Busan face a deadlock, with some countries pushing for production cuts while others resist. Dalit activists protest over Ambedkar Bhavan delay Dalit activists in Mysuru protested the delayed completion of Ambedkar Bhavan, confronting officials during Ambedkar's death anniversary. They demanded a written commitment from officials for the project's completion, citing escalating costs and alleged obstruction. The deputy commissioner stated a revised proposal was submitted, awaiting government approval for tendering. Stay updated with the latest news on Times of India . Don't miss daily games like Crossword , Sudoku , and Mini Crossword .
Title: Rolls-Royce Owner Donates Entire Tip After Being Hit: Spreading Love through Acts of Kindness
SAN DIEGO , Nov. 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCsTM), today announced that on November 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 117,000 shares of its common stock and 58,500 restricted stock units ("RSUs") to twelve (12) new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"). The awards were granted as inducements material to the employees entering into employment with Avidity in accordance with Nasdaq Listing Rule 5635(c)(4). The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Avidity, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with Avidity, pursuant to Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $43.65 per share, which is equal to the closing price of Avidity's common stock on The Nasdaq Global Market on November 20, 2024, or the vesting commencement date. The shares subject to the stock options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter, subject to each employee's continued employment with Avidity on such vesting dates. The RSUs will vest in four equal installments on the first four anniversaries of the vesting commencement date, subject to each employee's continued employment with Avidity on such vesting dates. The awards are subject to the terms and conditions of the 2022 Inducement Plan and the terms and conditions of a stock option agreement or RSU agreement, as applicable, covering the grant. About Avidity Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCsTM). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare neuromuscular diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly-owned precision cardiology development candidates addressing rare genetic cardiomyopathies. In addition, Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through key partnerships. Avidity is headquartered in San Diego, CA. For more information about our AOC platform, clinical development pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn and X . Investor Contact: Mike MacLean (619) 837-5014 investors@aviditybio.com Media Contact: Navjot Rai (619) 837-5016 media@aviditybio.com View original content to download multimedia: https://www.prnewswire.com/news-releases/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302313526.html SOURCE Avidity Biosciences, Inc.As delays plague Puerto Rico election certification process, judge issues rulingMoreover, Incremental Policy 2.0 emphasizes collaboration and partnership between government, businesses, and civil society. By fostering an inclusive and participatory policy-making process, policymakers can harness the collective wisdom and expertise of diverse stakeholders to co-create innovative solutions. This approach not only enhances the quality and relevance of policies but also ensures their successful implementation and impact.
In the world of professional football, success is not just measured by wins and losses, but also by the ability to navigate the challenges that come from within. For PSG, the current turmoil may be a test of their resilience and unity as a team. Whether they can rise above the distractions and come together in pursuit of their goals remains to be seen, but one thing is certain: Mbappe's determination to root out the moles and restore harmony within the squad will be instrumental in their journey towards redemption.
National Securities' Stock Trading App Crashes, System Failure Sparks User Discontent